Health Beyond Outcomes. Life Beyond Baseline. Vesalius is building the first publicly traded platform dedicated to peptide therapeutics — distributed through licensed physicians, anchored in regulatory-forward science.
Peptides are short amino-acid chains the body already knows how to read. They bind specific receptors and are studied for how they signal tissues — working with the body's own physiology rather than overriding it.
Subcutaneous, transdermal patch, intranasal, oral capsule, topical. Each format is selected per molecule — for the half-life, the target tissue, and the patient.
cGMP-aligned manufacturing, third-party verification, full chain of custody. The documentation a public company carries — and that grey-market vendors cannot match.
Descriptions of peptide mechanisms on this page are based on published scientific literature and are provided for educational purposes only. These are not claims of proven efficacy for any specific condition. All prescribing decisions are made by independent licensed clinicians.
On our path to becoming the first public company dedicated to innovating peptide science.
With a path to be first publicly traded company focused exclusively on peptides and longevity, Vesalius offers an unparalleled opportunity to invest in the future of human health.
Serving independent licensed healthcare providers with an end-to-end ecosystem including product fulfillment, and education.
Independent doctor distribution network across North America, Europe, UAE, Asia Pacific, and Latin America
Leadership team, Board of Directors, Scientific Advisory Board, and Special Advisory Board with unmatched expertise and global reach
Comprehensive portfolio of subcutaneous formulations, patches, nasal sprays, oral peptides, and topical formulations.
Led by clinical researchers, MDs, and biotech veterans, with deep formulation and delivery expertise.
Peptide science is moving fast, and building a rigorous, compliant platform to advance it responsibly is a rare opportunity in longevity medicine. That is what drew me to Vesalius.
Dr. Matt CookGlobal thought leader in regenerative medicineDr. Matt Cook is a co-founder of Vesalius Longevity Labs and holds an equity interest in the company. This statement reflects his clinical perspective and experience. Peptide therapeutics distributed through Vesalius have not been evaluated by the FDA to prevent, treat, cure, or diagnose any disease. Individual results vary and are not guaranteed.
Vesalius is engineered around the practitioner-patient relationship. Our peptide therapeutics are prescribed and supervised by licensed providers — not bought from a marketplace.
Peptides are precise — short amino acid sequences that signal specific physiologic pathways. We invest in the science that explains how, why, and at what dose.
What started as a regenerative medicine vision is now a global B2Doctor platform — with partners and advisors across North America, the UAE, Europe, Asia-Pacific, and Latin America.
The four-step chain that lets a publicly traded peptide company exist. Every step is documented, audited, and ready for inspection.
Most of what passed for the peptide category before 2024 was a grey-market supply chain dressed up as wellness. This is what changes when a public company enters the room.
Whether you are a solo licensed provider, a clinical network, or a telehealth operator — there is a path to work with us.
Regenerative, integrative, longevity, and functional medicine practitioners adding compliant peptide therapeutics to their practice.
Multi-site groups and concierge medicine networks looking for a credentialed, audit-ready supplier with consistent national fulfillment.
Co-branded therapeutic launches with telehealth leaders — bringing peptides to underserved populations.
